LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition

Abstract Background Hepatocellular carcinoma (HCC) is still one of the leading causes of cancer-related mortality worldwide. Sorafenib is commonly used as first-line systemic treatment for advanced HCC, but the clinical benefits fall victim to either primary or acquired drug resistance. Modulating f...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Jiunn-Chang Lin, Tun-Sung Huang, Yan-Bin Chen, Tung-Ying Chen, Pao-Shu Wu, Tsang-Pai Liu, Pei-Ming Yang
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2026-02-01
Σειρά:	Biology Direct
Θέματα:	LDN-57444 Sorafenib Hepatocellular carcinoma Ferroptosis HDAC2
Διαθέσιμο Online:	https://doi.org/10.1186/s13062-026-00735-1
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!